Astellas Pharma’s R&D program developed treatment for prostrate cancer & urinary frequency diseases

Astellas Pharma

Solutions - R&D

3: Good Health and Well-being3: Good Health and Well-being
Written by
2022-03-11 - Impact Rater Abdulmajeed V. Jan 16th, 2024
Reviewed by
2020-08-03 - Impact Analyst Luca L.

Research and development (R&D) investments assist in developing drugs that save lives1. Globally, prostate cancer (PC) is the 4th common cancer and affected 1.4 million (Mn) people in 20202,3. Annually, 546 Mn people are affected by Overactive bla...

Register to read the full analysis —or— Upgrade to access more features

Comments

There is no comment yet.

#Astellas Pharma #Xtandi #Breakthrough Drug #Myrbetriq

Actual Direct Impact

Assess the impact materiality of this Topic for Astellas Pharma

How negative/positive is the impact of Astellas Pharma for this Topic?

How would you rate the severity of this impact?

Scale (how grave the impact is)

Scope (how widespread the impact is)

Irremediability/Persistence (how difficult it is to counteract the impact)

Share this Analysis

Astellas Pharma

Solutions - R&D

3: Good Health and Well-being3: Good Health and Well-being
Written by
2022-03-11 - Impact Rater Abdulmajeed V. Jan 16th, 2024
Reviewed by
2020-08-03 - Impact Analyst Luca L.

Keen to rectify an issue with this analysis?